Adaptive Biotechnologies Lands $105,000,000 Series D Round

  • Feed Type
  • Date
    4/8/2014
  • Company Name
    Adaptive Biotechnologies
  • Mailing Address
    1551 Eastlake Avenue East Seattle, WA 98102 USA
  • Company Description
    Adaptive Biotechnologies’ platform technology breaks open the field of genomics immunology. T-cell receptor profiling using Adaptive’s proprietary technology and software allows scientists to study the adaptive immune system to an unprecedented depth via high-throughput T-Cell Receptor (TCR) sequencing.
  • Website
    http://www.adaptivebiotech.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $105,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    This investment will enable the Company to expand globally its preeminent immunosequencing research platform and downstream validated clinical diagnostic products.
  • M&A Terms
  • Venture Investor

By posting a comment, you agree to our terms and conditions.